Gary A Ulaner1, David M Hyman, Serge K Lyashchenko, Jason S Lewis, Jorge A Carrasquillo. 1. From the Departments of *Radiology and ‡Medicine, Memorial Sloan Kettering Cancer Center; Departments of †Radiology and §Medicine, Weill Cornell Medical College; and ∥Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: The aim of this study was to determine if imaging with Zr-trastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeting PET tracer, can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. METHODS: As part of an institutional review board-approved, prospective clinical trial of Zr-trastuzumab PET/CT (ClinicalTrials.gov identifier NCT02286843), a second group of 11 patients with HER2-negative primary breast cancer and known metastatic disease were recruited. Patients with confirmed HER2-negative primary breast cancer underwent Zr-trastuzumab PET/CT to screen for Zr-trastuzumab-avid lesions suggestive of unsuspected HER2-positive metastases. Zr-trastuzumab-avid lesions on PET/CT were biopsied and pathologically examined to determine HER2 status. RESULTS: All 11 patients had confirmed HER2-negative primary breast cancer. Four patients demonstrated suspicious foci on Zr-trastuzumab PET/CT. Of these 4 patients, 1 patient had biopsy-proven HER2-positive metastases. The other 3 patients with suspicious Zr-trastuzumab-avid foci had biopsy demonstrating a metastasis that was HER2-negative and were considered false-positive Zr-trastuzumab PET foci. Combined with a published report of the first 9 patients, there have been a total of 20 HER2-negative primary breast cancer patients, with 3 patients (15%) having pathologically confirmed HER2-positive distant metastases and 6 (30%) with suspicious Zr-trastuzumab-avid foci that were HER2-negative on pathology, which were thus considered false-positive Zr-trastuzumab findings. CONCLUSIONS: This second group of patients confirms the proof of concept that Zr-trastuzumab PET/CT detects unsuspected HER2-positive metastases in a subset of patients with HER2-negtive primary breast cancer. False-positive Zr-trastuzumab-avid foci present a challenge to using this tracer.
PURPOSE: The aim of this study was to determine if imaging with Zr-trastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeting PET tracer, can detect HER2-positive metastases in patients with HER2-negative primary breast cancer. METHODS: As part of an institutional review board-approved, prospective clinical trial of Zr-trastuzumab PET/CT (ClinicalTrials.gov identifier NCT02286843), a second group of 11 patients with HER2-negative primary breast cancer and known metastatic disease were recruited. Patients with confirmed HER2-negative primary breast cancer underwent Zr-trastuzumab PET/CT to screen for Zr-trastuzumab-avid lesions suggestive of unsuspected HER2-positive metastases. Zr-trastuzumab-avid lesions on PET/CT were biopsied and pathologically examined to determine HER2 status. RESULTS: All 11 patients had confirmed HER2-negative primary breast cancer. Four patients demonstrated suspicious foci on Zr-trastuzumab PET/CT. Of these 4 patients, 1 patient had biopsy-proven HER2-positive metastases. The other 3 patients with suspicious Zr-trastuzumab-avid foci had biopsy demonstrating a metastasis that was HER2-negative and were considered false-positive Zr-trastuzumab PET foci. Combined with a published report of the first 9 patients, there have been a total of 20 HER2-negative primary breast cancerpatients, with 3 patients (15%) having pathologically confirmed HER2-positive distant metastases and 6 (30%) with suspicious Zr-trastuzumab-avid foci that were HER2-negative on pathology, which were thus considered false-positive Zr-trastuzumab findings. CONCLUSIONS: This second group of patients confirms the proof of concept that Zr-trastuzumab PET/CT detects unsuspected HER2-positive metastases in a subset of patients with HER2-negtive primary breast cancer. False-positive Zr-trastuzumab-avid foci present a challenge to using this tracer.
Authors: Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen Journal: Nat Protoc Date: 2010-03-25 Impact factor: 13.491
Authors: Gary A Ulaner; David M Hyman; Dara S Ross; Adriana Corben; Sarat Chandarlapaty; Shari Goldfarb; Heather McArthur; Joseph P Erinjeri; Stephen B Solomon; Hartmuth Kolb; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: Naoki Niikura; Jun Liu; Naoki Hayashi; Elizabeth A Mittendorf; Yun Gong; Shana L Palla; Yutaka Tokuda; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: Stephen I Rudnick; Jianlong Lou; Calvin C Shaller; Yong Tang; Andres J P Klein-Szanto; Louis M Weiner; James D Marks; Gregory P Adams Journal: Cancer Res Date: 2011-03-15 Impact factor: 12.701
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Melissa A Deri; Shashikanth Ponnala; Paul Kozlowski; Benjamin P Burton-Pye; Huseyin T Cicek; Chunhua Hu; Jason S Lewis; Lynn C Francesconi Journal: Bioconjug Chem Date: 2015-11-25 Impact factor: 4.774
Authors: Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas Journal: Inorg Chem Date: 2020-11-10 Impact factor: 5.165
Authors: Gary A Ulaner; Serge K Lyashchenko; Christopher Riedl; Shutian Ruan; Pat B Zanzonico; Diana Lake; Komal Jhaveri; Brian Zeglis; Jason S Lewis; Joseph A O'Donoghue Journal: J Nucl Med Date: 2017-11-16 Impact factor: 10.057
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren Journal: Radiology Date: 2020-04-07 Impact factor: 11.105
Authors: Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith Journal: Semin Nucl Med Date: 2020-06-10 Impact factor: 4.446
Authors: Gary A Ulaner; Jorge A Carrasquillo; Christopher C Riedl; Randy Yeh; Vaios Hatzoglou; Dara S Ross; Komal Jhaveri; Sarat Chandarlapaty; David M Hyman; Brian M Zeglis; Serge K Lyashchenko; Jason S Lewis Journal: Radiology Date: 2020-06-09 Impact factor: 11.105
Authors: Elaheh Khozeimeh Sarbisheh; Akam K Salih; Shvan J Raheem; Jason S Lewis; Eric W Price Journal: Inorg Chem Date: 2020-07-28 Impact factor: 5.165